Puma Biotechnology
PBYI
156 hedge funds and large institutions have $1.64B invested in Puma Biotechnology in 2018 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 61 increasing their positions, 46 reducing their positions, and 39 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 46
8% more call options, than puts
Call options by funds: $35.4M | Put options by funds: $32.9M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.19% less ownership
Funds ownership: 95.31% → 94.12% (-1.2%)
10% less funds holding
Funds holding: 174 → 156 (-18)
23% less capital invested
Capital invested by funds: $2.13B → $1.64B (-$486M)
44% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$36.2M |
| 2 |
FAM
Fred Alger Management
New York
|
+$24.9M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$19.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$15.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$55.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$27.7M |
| 3 |
D.E. Shaw & Co
New York
|
-$25.7M |
| 4 |
Jennison Associates
New York
|
-$22.3M |
| 5 |
TCP
Tourbillon Capital Partners
New York
|
-$16.5M |
PBYI Hedge Fund Activity: Q3 2018 in Review
156 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2018, worth a combined $1.64B — down 23% from $2.13B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of PBYI and 22 opened new positions — a net loss of 17 holders — while 46 trimmed existing stakes and 61 added.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $36.2M. The largest seller was Janus Henderson Group, cutting an estimated $55.7M.
- 156 institutional investors held Puma Biotechnology (PBYI) as of Q3 2018, down from 174 in Q2 2018.
- Funds reported $1.64B of Puma Biotechnology stock for Q3 2018, down 23% quarter-over-quarter.
- 22 funds opened new Puma Biotechnology positions in Q3 2018 and 39 closed out, a net change of -17 holders.
- The largest Puma Biotechnology buyer in Q3 2018 was Camber Capital Management, an estimated $36.2M added.
- The largest Puma Biotechnology seller in Q3 2018 was Janus Henderson Group, an estimated $55.7M sold.
Based on aggregated 13F filings for Q3 2018.